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Abstract. Background/Aim: Malignant diseases present a
significant public health burden worldwide and their
treatment is further complicated by the phenomenon of
multidrug resistance. Derivatives of imidazopyridine exhibit
several remarkable pharmacological activities and they could
reverse the multidrug resistance of cancer cells due to
overexpressing P-glycoprotein. Materials and Methods: A
series of novel imidazo[4,5-b]pyridine derivatives were
synthesized and their biological activities were evaluated in
vitro using parental (PAR) and multidrug resistant (MDR;
ABCB1-overexpressing) mouse T-lymphoma cells. The
cytotoxic activity and selectivity of the tested compounds
were assessed by the thiazolyl blue tetrazolium bromide
(MTT) assay, the ABCB1 modulating activity was measured
by rhodamine 123 accumulation assay using flow cytometry.
Results: Six compounds (b, c, d, f, h and i) showed moderate-
to-high cytotoxic activity on the tested cell lines, while
derivative i presented with promising selectivity towards the
MDR cell line. Derivatives a, d, f, g and i were proven to be
effective modulators of the ABCB1 multidrug efflux pump,
with two compounds showing efflux pump modulatory activity
at 2 μM concentration. Conclusion: Based on our
experimental results, compounds that showed potent activity
are those with a short carbon side chain; a methoxy group
on the benzene ring; a heterocyclic (triazole) side chain and
the presence of an alkylated N-atom at position 4.
Malignant diseases present a significant public health burden
worldwide, and even with the therapeutic armamentarium of
surgical interventions, radiation therapy and chemotherapeutic
treatment, these diseases still represent the second major
cause of mortality in the developed world (1). The emergence
of cancer cells that are resistant to structurally and
functionally unrelated cytostatic drugs (this phenotype is
termed multidrug resistance or MDR) further complicated the
treatment of these diseases (2). A common mechanism for the
reduction of chemotherapeutic efficacy is the overexpression
of ATP-binding cassette (ABC) drug transporters (3).
Compounds containing the imidazo[4,5-b]pyridine moiety
have been reported for various activities such as anticancer (4-
6), antiviral (7-9) antimitotic (10), anti-inflammatory (11, 12)
and tuberculostatic (13, 14). In addition, imidazo[4,5-b]pyridine
may act as an antagonist of various biological receptors (15)
including angiotensin-II, platelet activating factor (PAF) (16),
subtype metabotropic glutamate V3 (17), AT1 receptor (18) and
adenosine A2a (19). The imidazo[4,5-b]pyridine heterocyclic
system is also a structural analogue of purine, whose derivatives
readily interact with large biomolecules such as DNA, RNA and
proteins in vivo. The structural homology with the adenine
nucleus would allow imidazopyridine derivatives to be able to
reverse multidrug resistance by inhibiting the activity of P-
glycoprotein (ABCB1) (20). 
In the present study, a series of newly-synthesized
imidazo[4,5-b]pyridine derivatives (9 compounds) were
investigated regarding their cytotoxicity and their ABCB1-
modulating properties against parental and ABCB1-
overexpressing MDR mouse T-lymphoma cells in vitro.
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Materials and Methods
Compounds. The imidazo[4,5-b]pyridine derivatives tested were
synthesized by alkylation (Figure 1A) and 1,3-dipolar cycloaddition
(Figure 1B). Condensation of 5-bromo-2,3-diaminopyridine with 4-
chlorobenzaldehyde or 4-methoxybenzaldehyde in water for 48 h at
100˚C in the presence of I2 resulted in Derivative 1 (21). Derivatives
2, 2’, 3 were obtained by the reaction of Derivative 1 with mono-
halogenated reagents under phase transfer catalysis conditions, using
tetra-n-butylammonium bromide (BTBA) as a catalyst, K2CO3 as a
base and N,N-dimethylformamide as solvent (22). Derivative 4 was
obtained by the condensation of azides with acetylenic compounds
by 1,3-dipolar cycloaddition. Substituents of the tested compounds,
reaction yields and melting points are shown in Table I. Compounds
were solved in DMSO to obtain stock solutions. Afterwards, working
solutions were prepared by dilution in water, the concentration of
DMSO was below 1% in all the experiments. 
Other chemicals used in the study as reagents were: 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-
Aldrich, St Louis, MO, USA), sodium dodecyl sulphate (SDS; Sigma-
Aldrich, St Louis, MO, USA), rhodamine 123 (R123; Sigma, St.
Louis, MO, USA), verapamil (EGIS Hungarian Pharmaceutical
Company, Budapest, Hungary) and dimethyl sulfoxide (DMSO;
Sigma-Aldrich, St Louis, MO, USA). Stock solutions of R123 were
prepared in phosphate buffered saline and verapamil was dissolved
in water. All solutions were prepared on the day of the assay.
Cell lines. L5178Y mouse T-cell lymphoma cells (PAR) (ECACC
Cat. No. 87111908, obtained from FDA, Silver Spring, MD, USA)
were transfected with pHa MDR1/A retrovirus, as previously
described by Cornwell et al. (23). The ABCB1-expressing cell line
L5178Y (MDR) was selected by culturing the infected cells with
colchicine. The L5178Y human ABCB1-transfected subline was
cultured in McCoy’s 5A medium (Sigma-Aldrich, St Louis, MO,
USA) supplemented with 10% heat-inactivated horse serum (Sigma-
Aldrich), 200 mM L-glutamine (Sigma-Aldrich) and a penicillin-
streptomycin (Sigma-Aldrich) mixture in concentrations of 100 U/l
and 10 mg/l, respectively. The cell lines were incubated at 37˚C, in a
5% CO2, 95% air atmosphere.
Assay for cytotoxic effect. The effects of increasing concentrations of
the tested imidazo[4,5-b]pyridine derivatives on cell growth were
evaluated in 96-well microtiter plates. The parental (PAR) and
multidrug resistant (MDR) mouse T-lymphoma cells were cultured
using McCoy’s 5A medium supplemented with 10% heat-inactivated
horse serum. The density of the cells was adjusted to 1x104 cells per
well (in 100 μl of medium per well) and then added to the 96-well
flat-bottomed microtiter plates containing the dilutions of the tested
compounds. The culture plates were incubated at 37˚C, in a 5% CO2,
95% air atmosphere. 
The culture plates were incubated at 37˚C for 24 h; at the end of
the incubation period, 20 μl of MTT (Sigma) solution (from a stock
solution of 5 mg/ml) were added to each well. After incubation at
37˚C for 4 h, 100 μl of sodium dodecyl sulfate (SDS) (Sigma)
solution (10% in 0.01 M HCI) were added to each well and the
plates were further incubated at 37˚C overnight. Cell growth was
determined by measuring the optical density (OD) at 540/630 nm
with Multiscan EX ELISA reader (Thermo Labsystems, Cheshire,
WA, USA) (24). Inhibition of the cell growth was determined
according to the formula below:
Rhodamine 123 accumulation assay. The following method is based
on a fluorescence-based detection system which uses verapamil as
reference inhibitor of the ABCB1 efflux pump (25). The parental and
multidrug resistant (MDR) subline of mouse T-lymphoma cells were
adjusted to a density of 2×106 cells/ml and re-suspended in serum-free
McCoy’s 5A medium and distributed in 500 μl aliquots. The tested
compounds (1 and 10 μl from a stock solution of 1 mM, respectively)
were added at different concentrations (final concentrations of 2 μM
and 20 μM, respectively), and the samples were incubated for 10 min
at room temperature. Verapamil was used as positive control at 20 μM
(from a 5 mg/ml stock solution) and DMSO was used as solvent
control (at 2 V/V%). After the first incubation period, 10 μl (5.2 μM
final concentration) of rhodamine 123 were added to the samples and
the cells were further incubated for 20 min at 37˚C, washed twice with
phosphate buffered saline (PBS) and re-suspended in 1 ml PBS for
analysis. The fluorescence intensity of the gated cell population was
measured with a Partec CyFlow flow cytometer (Partec, Munster,
Germany). The mean fluorescence intensity was calculated for the
treated MDR and parental mouse T-lymphoma cells lines as compared
to the untreated cells (26, 27). The fluorescence activity ratio (FAR)
was calculated based on the following equation which relates the
measured fluorescence values:
Results
The IC50 values (thus, the cytotoxic activity) of the tested
compounds on the parental subline of the mouse T-lymphoma
cells can be divided into three groups: compounds with IC50
values above 100 μM (a and e), compounds with IC50 values
between 20-70 μM (in decreasing order: c, g, f, b, d and h) and
derivative i, which presented with an IC50 value of 1.73 μM.
The IC50 values of the tested compounds on the MDR mouse
T-lymphoma cells can be divided in a comparable way
(compounds with IC50 values above 100 μM: a, e and g;
compounds with IC50 values between 10-75 μM: c, b, f, d and
h; and derivative i, which presented with an IC50 value of 
0.20 μM) (Table II). While the majority of the compounds had
no selective cytotoxicity against the efflux pump
overexpressing subline of mouse lymphoma cells (with
IC50MDR values higher than IC50PAR; SI values ranging
between 0.55 and 1.49), derivative i, which was proven to be
the most cytotoxic among the tested imidazo[4,5-b]pyridine
derivatives (IC50PAR=1.73 μM, IC50MDR=0.20 μM) showed
potent selectivity (SI=8.66) towards the MDR cells (Table II).
Out of the 9 tested imidazo[4,5-b]pyridine derivatives, 5
compounds (a, d, f, g and i) presented with potent ABCB1-
modulating activity (the intracellular concentration of
rhodamine 123 was increased) at the same concentration as
verapamil (20 μM), surpassing the activity of the positive
control by a considerable margin (with FAR values ranging
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between 19.65 and 57.55 vs. FARverapamil=11.83). Based on
the results presented in Table III, the potency of the active
compounds is 1.66-4.86-fold higher than verapamil’s. In some
cases, the efflux pump modulating activity of the compounds
approaches (i, FAR quotient: 89.50%) or surpasses (a, FAR
quotient: 143.35%) the activity of the positive control at
concentrations that are ten times smaller (Table III). The case
of compound a is especially compelling, because despite the
fact that this compound was not the most potent inhibitor of
the ABCB1 transporter among the tested derivatives (FAR20
μM=28.09), it exerted its activity without any toxicity (IC50
>100 μM) on the tested cell lines.
Discussion
Compounds containing the imidazo[4,5-b]pyridine moiety
represent a special group of compounds with numerous
pharmacological activities (28, 29, 30). In the present study,
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Figure 1. Synthesis of imidazo[4,5-b]pyridines derivatives synthesized by alkylation (A) and 1,3-dipolar cycloaddition (B). 
Table I. Substituents of novel imidazo[4,5-b]pyridine derivatives.
Compound                                R’                                                R                                            N*                Reaction yield (%)           Melting point (˚C)
a                                                Cl                                             C8H17                                         3                               66                                    96-98
b                                                Cl                                            C12H25                                        3                               36                                    80-82
c                                                Cl                                            C12H25                                        4                               36                                    78-80
d                                            OCH3                                          C4H9                                          3                               72                                   92-94 
e                                                Cl                                             C8H17                                         3                               70                                    76-78
f                                                 Cl                                                                                                4                               40                                 162-164
g                                             OCH3                                                                                             3                               45                                 130-132
h                                                Cl                                                                                                3                               65                                 186-188
i                                              OCH3                                                                                             3                               60                                 212-214
the anticancer and efflux pump modulating activity of nine
novel imidazo[4,5-b]pyridine derivatives were evaluated. Five
compounds (c, b, f, d and h) showed moderate cytotoxicity
on the MDR cell line, while derivative i presented with potent
selectivity and a very low IC50 value. 
Five of these compounds exhibited significantly better
MDR-reversing activity than the reference (verapamil) with a
fluorescence ratio of 19.65 to 57.55 compared with 11.83 for
verapamil. It should be noted that compounds that lack the
potent efflux pump modulatory activity of their counterparts
are those with a long carbon chain in position 3 or 4 (n>4C),
which suggests that this moiety is not suitable for pronounced
activity. Both compounds h and i are alkylated at the same
position with a propargyl group, however, i has a methoxy and
h has chlorine group. By comparing their activity of ABCB1
pump inhibition, it can be deduced that the methoxy group is
the most favorable for activity. However, the activity of
compound f is greater than that of product g. This amelioration
of activity for the compound containing a chlorine group can
be attributed to the position of the carbon chain (f at position
4, g at position 3). This suggests that alkylation at the 4-
position would be better for the MDR-reversing activity. In
addition, compounds a and e both have a long side chain, but
for product a, the chain is carried by a triazole group.
Therefore, the presence of heteroatoms on the side chain, in
particular nitrogen, improves the MDR-reversing activity of
the imidazo[4,5-b]pyridine derivatives. It can be concluded
that the novel imidazo[4,5-b]pyridine derivatives presented
with potent MDR-reversing activities together with anticancer
properties to a varying degree. For additional understanding
of the structure-activity relationships (SAR) of these
compounds, the synthesis of additional derivatives and further
biological assays are warranted.
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